Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (
Sign Up to like & getrecommendations! Published in 2022 at "Haemophilia"
DOI: 10.1111/hae.14563
Abstract: Eptacog beta is a new recombinant activated human factor VII bypassing agent approved in the United States for the treatment and control of bleeding in patients with haemophilia A or B with inhibitors 12 years… read more here.
Keywords: haemophilia inhibitors; eptacog beta; control bleeding; treatment control ... See more keywords